Lumican: a new inhibitor of matrix metalloproteinase-14 activity.
Katarzyna Pietraszek, Aurore Chatron-Colliet, Stéphane Brézillon, Corinne Perreau, Anna Jakubiak-Augustyn, Hubert Krotkiewski, François-Xavier Maquart, Yanusz Wegrowski
Index: FEBS Lett. 588(23) , 4319-24, (2014)
Full Text: HTML
Abstract
We previously showed that lumican regulates MMP-14 expression. The aim of this study was to compare the effect of lumican and decorin on MMP-14 activity. In contrast to decorin, the glycosylated form of lumican was able to significantly decrease MMP-14 activity in B16F1 melanoma cells. Our results suggest that a direct interaction occurs between lumican and MMP-14. Lumican behaves as a competitive inhibitor which leads to a complete blocking of the activity of MMP-14. It binds to the catalytic domain of MMP-14 with moderate affinity (KD∼275 nM). Lumican may protect collagen against MMP-14 proteolysis, thus influencing cell-matrix interaction in tumor progression.Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
Related Compounds
Related Articles:
2014-12-16
[Nucleic Acids Res. 42(22) , 14022-30, (2014)]
The dynamics of giant unilamellar vesicle oxidation probed by morphological transitions.
2014-10-01
[Biochim. Biophys. Acta 1838(10) , 2615-24, (2014)]
2015-01-01
[Drug Dev. Ind. Pharm. 41(1) , 156-62, (2014)]
2014-01-01
[PLoS ONE 9(11) , e112818, (2014)]
2015-03-01
[Tissue Eng. Part A 21(5-6) , 948-59, (2015)]